Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction.

52 A phase-2 controlled study conducted during 4 weeks in 196 patients with noncancer pain and OIC found an increase in the number of complete spontaneous BM in patients treated with prucalopride at a daily dose of 2–4 mg compared to placebo, but the difference did not reach statistical significance. 53 Both itopride and prucalopride do not interfere with cardiac functioning.

also in 111,027 other papers